IMNN vs. ACST, PLUR, DRRX, ATRA, LSB, BTAI, YS, TPST, INAB, and CUE
Should you be buying Imunon stock or one of its competitors? The main competitors of Imunon include Acasti Pharma (ACST), Pluri (PLUR), DURECT (DRRX), Atara Biotherapeutics (ATRA), Lakeshore Biopharma (LSB), BioXcel Therapeutics (BTAI), YS Biopharma (YS), Tempest Therapeutics (TPST), IN8bio (INAB), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry.
Imunon (NASDAQ:IMNN) and Acasti Pharma (NASDAQ:ACST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.
In the previous week, Acasti Pharma had 1 more articles in the media than Imunon. MarketBeat recorded 3 mentions for Acasti Pharma and 2 mentions for Imunon. Imunon's average media sentiment score of 1.44 beat Acasti Pharma's score of 0.29 indicating that Imunon is being referred to more favorably in the media.
Acasti Pharma has lower revenue, but higher earnings than Imunon. Acasti Pharma is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.
Imunon currently has a consensus target price of $12.00, indicating a potential upside of 943.48%. Acasti Pharma has a consensus target price of $6.00, indicating a potential upside of 117.39%. Given Imunon's higher probable upside, analysts clearly believe Imunon is more favorable than Acasti Pharma.
Acasti Pharma's return on equity of -13.24% beat Imunon's return on equity.
4.5% of Imunon shares are held by institutional investors. Comparatively, 6.1% of Acasti Pharma shares are held by institutional investors. 5.0% of Imunon shares are held by company insiders. Comparatively, 13.5% of Acasti Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Imunon has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Acasti Pharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
Acasti Pharma received 302 more outperform votes than Imunon when rated by MarketBeat users. However, 100.00% of users gave Imunon an outperform vote while only 70.52% of users gave Acasti Pharma an outperform vote.
Summary
Acasti Pharma beats Imunon on 8 of the 14 factors compared between the two stocks.
Get Imunon News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMNN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
Free IMNN Stock Alerts